Evidence map›Paper›PMID 36804034›Full record

ArticleCritical care (London, England)2023

Response to the Letter by Spurling and Colleagues.

Craig I Coleman, Olivia S Costa, Stuart J Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J Christoph-Schubel, Belinda Lovelace

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Craig I ColemanDepartment of Pharmacy Practice, University of Connecticut School of Pharmacy, 69 North Eagleville Road, Unit 3092, Storrs, CT, 06269, USA. craig.coleman@hhchealth.org.
Olivia S CostaDepartment of Pharmacy Practice, University of Connecticut School of Pharmacy, 69 North Eagleville Road, Unit 3092, Storrs, CT, 06269, USA.
Stuart J ConnollyMcMaster University, Hamilton, ON, Canada.
Mukul SharmaMcMaster University, Hamilton, ON, Canada.
Jan Beyer-WestendorfThrombosis and Anticoagulation Service, Division Hematology and Hemostaseology, Department of Medicine I, Dresden University Hospital, Dresden, Germany.
Mary J Christoph-SchubelDepartment of Global Medical and Payer Evidence, AstraZeneca Pharmaceuticals, South San Francisco, CA, USA.
Belinda LovelaceDepartment of Health Economics and Payer Evidence, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

RivaroxabanBlood Coagulation FactorsFactor XaHumansPropensity ScorePyrazolesPyridonesRecombinant ProteinsapixabanBlood Coagulation FactorsFactor Xaprothrombin complex concentratesPRT064445PyrazolesPyridonesRecombinant ProteinsRivaroxaban

Identifiers

PMID36804034
PMCPMC9940403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.